Resultados de procura - Piris, Adriano
- Mostrando 1 - 16 Resultados de 16
-
1
-
2
Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families por Njauw, Ching-Ni Jenny, Kim, Ivana, Piris, Adriano, Gabree, Michele, Taylor, Michael, Lane, Anne Marie, DeAngelis, Margaret M., Gragoudas, Evangelos, Duncan, Lyn M., Tsao, Hensin
Publicado 2012Text -
3
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado 2013Text -
4
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma por Shen, Che-Hung, Kim, Sun Hye, Trousil, Sebastian, Frederick, Dennie T., Piris, Adriano, Yuan, Ping, Cai, Li, Gu, Lei, Li, Man, Lee, Jung Hyun, Mitra, Devarati, Fisher, David E., Sullivan, Ryan J., Flaherty, Keith T., Zheng, Bin
Publicado 2016Text -
5
Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: A case series por Rrapi, Renajd, Chand, Sidharth, Gaffney, Rebecca, Lo, Jennifer A., Smith, Jeffrey S., Xia, Fan Di, Chen, Steven T., Duncan, Lyn M., Foreman, Ruth K., Hartman, Rebecca I., Hoang, Mai P., Piris, Adriano, Walls, Andrew C., Kroshinsky, Daniela
Publicado 2021Text -
6
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma por Mooradian, Meghan J., Reuben, Alexandre, Prieto, Peter A., Hazar-Rethinam, Mehlika, Frederick, Dennie T., Nadres, Brandon, Piris, Adriano, Juneja, Vikram, Cooper, Zachary A., Sharpe, Arlene H., Corcoran, Ryan B., Flaherty, Keith T., Lawrence, Donald P., Wargo, Jennifer A., Sullivan, Ryan J.
Publicado 2018Text -
7
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade por Cooper, Zachary A., Juneja, Vikram R., Sage, Peter T., Frederick, Dennie T., Piris, Adriano, Mitra, Devarati, Lo, Jennifer A., Hodi, F. Stephen, Freeman, Gordon J., Bosenberg, Marcus W., McMahon, Martin, Flaherty, Keith T., Fisher, David E., Sharpe, Arlene H., Wargo, Jennifer A.
Publicado 2014Text -
8
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors por Oberholzer, Patrick A., Kee, Damien, Dziunycz, Piotr, Sucker, Antje, Kamsukom, Nyam, Jones, Robert, Roden, Christine, Chalk, Clinton J., Ardlie, Kristin, Palescandolo, Emanuele, Piris, Adriano, MacConaill, Laura E., Robert, Caroline, Hofbauer, Günther F.L., McArthur, Grant A., Schadendorf, Dirk, Garraway, Levi A.
Publicado 2012Text -
9
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib por Corcoran, Ryan B., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandria P., Brown, Ronald D., Pelle, Patricia Della, Dias-Santagata, Dora, Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A.
Publicado 2012Text -
10
Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma por Starrett, Gabriel J., Thakuria, Manisha, Chen, Tianqi, Marcelus, Christina, Cheng, Jingwei, Nomburg, Jason, Thorner, Aaron R., Slevin, Michael K., Powers, Winslow, Burns, Robert T., Perry, Caitlin, Piris, Adriano, Kuo, Frank C., Rabinowits, Guilherme, Giobbie-Hurder, Anita, MacConaill, Laura E., DeCaprio, James A.
Publicado 2020Text -
11
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma por Corcoran, Ryan B., Rothenberg, Stephen Michael, Hata, Aaron N., Faber, Anthony C., Piris, Adriano, Nazarian, Rosalynn M., Brown, Ronald D., Godfrey, Jason T., Winokur, Daniel, Walsh, John, Mino-Kenudson, Mari, Maheswaran, Shyamala, Settleman, Jeffrey, Wargo, Jennifer A., Flaherty, Keith T., Haber, Daniel A., Engelman, Jeffrey A.
Publicado 2013Text -
12
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors por Konieczkowski, David J., Johannessen, Cory M., Abudayyeh, Omar, Kim, Jong Wook, Cooper, Zachary A., Piris, Adriano, Frederick, Dennie T., Barzily-Rokni, Michal, Straussman, Ravid, Haq, Rizwan, Fisher, David E., Mesirov, Jill P., Hahn, William C., Flaherty, Keith T., Wargo, Jennifer A., Tamayo, Pablo, Garraway, Levi A.
Publicado 2014Text -
13
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming por Chu, Zhaowei, Gu, Lei, Hu, Yeguang, Zhang, Xiaoyang, Li, Man, Chen, Jiajia, Teng, Da, Huang, Man, Shen, Che-Hung, Cai, Li, Yoshida, Toshimi, Qi, Yifeng, Niu, Zhixin, Feng, Austin, Geng, Songmei, Frederick, Dennie T., Specht, Emma, Piris, Adriano, Sullivan, Ryan J., Flaherty, Keith T., Boland, Genevieve M., Georgopoulos, Katia, Liu, David, Shi, Yang, Zheng, Bin
Publicado 2022Text -
14
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma por Frederick, Dennie Tompers, Piris, Adriano, Cogdill, Alexandria P., Cooper, Zachary A., Lezcano, Cecilia, Ferrone, Cristina R., Mitra, Devarati, Boni, Andrea, Newton, Lindsay P., Liu, Chengwen, Peng, Weiyi, Sullivan, Ryan J, Lawrence, Donald P., Hodi, F. Stephen, Overwijk, Willem W., Lizée, Gregory, Murphy, George F., Hwu, Patrick, Flaherty, Keith T., Fisher, David E., Wargo, Jennifer A.
Publicado 2013Text -
15
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma por Simpson, R Mark, Bastian, Boris C, Michael, Helen T, Webster, Joshua D, Prasad, Manju L, Conway, Catherine M, Prieto, Victor M, Gary, Joy M, Goldschmidt, Michael H, Esplin, D Glen, Smedley, Rebecca C, Piris, Adriano, Meuten, Donald J, Kiupel, Matti, Lee, Chyi-Chia R, Ward, Jerrold M, Dwyer, Jennifer E, Davis, Barbara J, Anver, Miriam R, Molinolo, Alfredo A, Hoover, Shelley B, Rodriguez-Canales, Jaime, Hewitt, Stephen M
Publicado 2014Text -
16
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids por Jenkins, Russell W., Aref, Amir R., Lizotte, Patrick H., Ivanova, Elena, Stinson, Susanna, Zhou, Chensheng W., Bowden, Michaela, Deng, Jiehui, Liu, Hongye, Miao, Diana, He, Meng Xiao, Walker, William, Zhang, Gao, Tian, Tian, Cheng, Chaoran, Wei, Zhi, Palakurthi, Sangeetha, Bittinger, Mark, Vitzthum, Hans, Kim, Jong Wook, Merlino, Ashley, Quinn, Max, Venkataramani, Chandrasekar, Kaplan, Joshua A., Portell, Andrew, Gokhale, Prafulla C., Phillips, Bart, Smart, Alicia, Rotem, Asaf, Jones, Robert E., Keogh, Lauren, Anguiano, Maria, Stapleton, Lance, Jia, Zhiheng, Barzily-Rokni, Michal, Cañadas, Israel, Thai, Tran C., Hammond, Marc R., Vlahos, Raven, Wang, Eric S., Zhang, Hua, Li, Shuai, Hanna, Glenn J., Huang, Wei, Hoang, Mai P., Piris, Adriano, Eliane, Jean-Pierre, Stemmer-Rachamimov, Anat O., Cameron, Lisa, Su, Mei-Ju, Shah, Parin, Izar, Benjamin, Thakuria, Manisha, LeBoeuf, Nicole R., Rabinowits, Guilherme, Gunda, Viswanath, Parangi, Sareh, Cleary, James M., Miller, Brian C., Kitajima, Shunsuke, Thummalapalli, Rohit, Miao, Benchun, Barbie, Thanh U., Sivathanu, Vivek, Wong, Joshua, Richards, William G., Bueno, Raphael, Yoon, Charles H., Miret, Juan, Herlyn, Meenhard, Garraway, Levi A., Van Allen, Eliezer M., Freeman, Gordon J., Kirschmeier, Paul T., Lorch, Jochen H., Ott, Patrick A., Hodi, F. Stephen, Flaherty, Keith T., Kamm, Roger D., Boland, Genevieve M., Wong, Kwok-Kin, Dornan, David, Paweletz, Cloud Peter, Barbie, David A.
Publicado 2017Text